

REMARKS

By this preliminary amendment, the specification is amended to incorporate Applicants' claim of priority. The specification is also amended on page 4, line 9 to clarify an abbreviation. Support for this amending language can be found throughout the specification, specifically on page 11, line 33. On page 6, lines 4-5 the specification is amended to correct a typographical error, on page 8, line 32 to clarify that the cited patent is a Japanese patent, and on page 10, line 22 to remove a link to a web site.

Also by this preliminary amendment, claims 1, 3-6, and 8 are amended. Claim 3 is amended solely to remove multiple dependencies. Support for the amending language of claim 1 is found throughout the specification, specifically on page 8, line 28 to page 10, line 33. Support for the amending language of claim 4 is found throughout the specification, specifically on page 11, lines 22-29. Support for the amending language of claim 5 is found throughout the specification, specifically on page 12, lines 13-27. Support for the amending language of claim 6 is found throughout the specification, specifically on page 11, line 1 to page 12, line 27. Support for the amending language of claim 8 is found throughout the specification, specifically on page 12, lines 13-27.

New claim 11 is added by this preliminary amendment. Support for new claim 11 is found throughout the specification, specifically on page 11, line 1 to page 12, line 27.

Claims 9 and 10 are cancelled, without prejudice to renewal.

Title of the Invention

Applicants note that the title of the invention as listed in the English translation of the PCT application accompanying this filing under 35 U.S.C. § 371 differs from the title of the published PCT application. Applicants request that the title of the invention as listed in the English translation of the PCT application be used, specifically: "AGENTS FOR GENE THERAPY OF CEREBROVASCULAR DISORDERS."

Conclusion

No new matter has been added by this amendment. Applicants request that this application be examined. If any formal matters need to be discussed, the Applicants request that the U.S. Patent and Trademark Office contact the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



David Cash, Ph.D.
Registration No. 52,706

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 228-9446